Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Amado Zurita-Saavedra"'
Autor:
Andrew L. Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, Paul Corn, Amado Zurita‐Saavedra, Landon C. Brown, Chester Kao, Emily N. Kinsey, Rajan T. Gupta, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, Nizar Tannir, Pavlos Msaouel, Amishi Shah, Tian Zhang, Matthew T. Campbell
Publikováno v:
Cancer Medicine, Vol 10, Iss 7, Pp 2341-2349 (2021)
Abstract Introduction Two separate antiangiogenic tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) combinations are FDA‐approved as front‐line treatment for metastatic renal cell carcinoma (mRCC). Little is known about off‐protocol and
Externí odkaz:
https://doaj.org/article/93fb0ccf60b5470ca6cdd487ce1a82ce
Autor:
John V. Heymach, Amado Zurita‐Saavedra, Scott Kopetz, Tina Cascone, Monique Nilsson, Irene Guijarro
Publikováno v:
Holland‐Frei Cancer Medicine. :1-30
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48cea241d81632144b44b8c7457f80f3
https://doi.org/10.1002/9781119000822.hfcm017.pub2
https://doi.org/10.1002/9781119000822.hfcm017.pub2
Autor:
Jose A. Karam, Pavlos Msaouel, Brian De, Matthew T. Campbell, Jennifer Wang, Christopher G. Wood, Surena F. Matin, Amishi Yogesh Shah, Andrew J. Bishop, Jing Li, Quynh Nhu Nguyen, Debra Nana Yeboa, Amado Zurita-Saavedra, Chad Tang, Aradhana M. Venkatesan, Eric Jonasch, Nizar M. Tannir, Amol J. Ghia
Publikováno v:
BJU Int
Objective To study whether delivering definitive radiotherapy to sites of oligoprogression in metastatic renal cell carcinoma enabled deferral of systemic therapy changes without compromising disease control or survival. Materials/methods We identifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a96877ce75e3a71ee81ad88031b5a98
https://doi.org/10.1111/bju.15541
https://doi.org/10.1111/bju.15541
Autor:
Shoujie Chai, Nicholas Matsumoto, Ryan Storgard, Chen-Ching Peng, Ana Aparicio, Benjamin Ormseth, Kate Rappard, Cunningham Kate, Anand Kolatkar, Rafael Nevarez, Kai Han Tu, Ching-Ju Hsu, Amin Naghdloo, Paymaneh Malihi, Liya Xu, Paul Corn, Amado Zurita-Saavedra, James Hicks, Carmen Ruiz-Velasco, Peter Kuhn
Publikováno v:
Cancer Research. 82:1957-1957
Background: The mutation, selection, and adaptation of tumor cells along disease progression exhibits a spectrum of phenotypic and genotypic heterogeneity. The importance of distinguishing phenotypic states of CTC in addition to genomic alterations h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1fa64075a67e505d8314f66947718b9
https://doi.org/10.1158/1538-7445.am2022-1957
https://doi.org/10.1158/1538-7445.am2022-1957
Autor:
Spyridon P. Basourakos, Salman Syed, Amado Zurita-Saavedra, Zimu Gong, Jessica Lee Garcia, Faisal Ali
Publikováno v:
American Journal of Clinical Oncology. 43:87-93
INTRODUCTION Small cell prostate cancer (SCPC) is a rare histologic subtype of prostate cancer, for which the optimal staging strategy remains unclear. METHOD The Surveillance, Epidemiology, and End Results database was used to analyze the incidence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ea7ad12ac84dbcd080da9d6746baf44
https://doi.org/10.1097/coc.0000000000000631
https://doi.org/10.1097/coc.0000000000000631
Autor:
Matthew T. Campbell, Landon C. Brown, Emily N. Kinsey, Rajan T. Gupta, Andrew J. Armstrong, Amado Zurita-Saavedra, Benjamin Garmezy, Jianjun Gao, Tian Zhang, Michael R. Harrison, Minas Economides, Paul G. Corn, Lianchun Xiao, Amishi Yogesh Shah, Pavlos Msaouel, Daniel J. George, Chester Kao, Nizar M. Tannir, Aradhana M. Venkatesan, Andrew Leonard Laccetti, Eric Jonasch
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 7, Pp 2341-2349 (2021)
Cancer Medicine, Vol 10, Iss 7, Pp 2341-2349 (2021)
Introduction Two separate antiangiogenic tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) combinations are FDA‐approved as front‐line treatment for metastatic renal cell carcinoma (mRCC). Little is known about off‐protocol and post‐fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dd80d59c0758980da3e08cfff4b4615
https://pubmed.ncbi.nlm.nih.gov/33650321
https://pubmed.ncbi.nlm.nih.gov/33650321
Autor:
Jordi Rodon, Roman Groisberg, Apostolia Maria Tsimberidou, Timothy A. Yap, Andrew W. Hahn, Vivek Subbiah, Omar Alhalabi, Aung Naing, Funda Meric-Bernstam, Amishi Yogesh Shah, Nizar M. Tannir, Samantha C. Berkey, Amado Zurita-Saavedra, Shizhen Zhang, Shubham Pant
Publikováno v:
Cancer Research. 81:CT109-CT109
Introduction: Pre-clinical models show that the addition of the mTORC1/2 inhibitor sapanisertib (TAK-228) restores sensitivity to platinum chemotherapy and dramatically enhances paclitaxel-induced cancer cell killing. Carboplatin plus paclitaxel is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::597e18cf118a506e18d4fd9c26433dea
https://doi.org/10.1158/1538-7445.am2021-ct109
https://doi.org/10.1158/1538-7445.am2021-ct109
Autor:
G. Wilding, Nathaniel Wilganowski, Evan N. Cohen, Mark Titus, James M. Reuben, Sumankalai Ramachandran, Samantha Robertson, Hirak S. Basu, Amado Zurita-Saavedra
Publikováno v:
Cancer Research. 80:4791-4791
Background: Most cancer cells depend more on glycolysis for their energy need compared with their normal counterparts incubated under identical condition. In addition to glycolysis, tumor cells also engage mitochondrial ox-phos to support growth. Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42cf49e215b04b5a29d80bbfa196ef0c
https://doi.org/10.1158/1538-7445.am2020-4791
https://doi.org/10.1158/1538-7445.am2020-4791
Autor:
Xuemei Wang, John F. Ward, Surena F. Matin, John W. Davis, Curtis A. Pettaway, Stephen B. Williams, Brian F. Chapin, Amado Zurita-Saavedra, Mary Achim, Louis L. Pisters
Publikováno v:
Clinical Genitourinary Cancer. 14:130-138
Background Multimodality therapies for men with high- and very high-risk prostate cancer, including neoadjuvant systemic therapy followed by subsequent radical prostatectomy (RP) are being increasingly explored despite the lack of adequate morbidity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b61c75382e8bf92554b9db0f72707deb
https://doi.org/10.1016/j.clgc.2015.10.008
https://doi.org/10.1016/j.clgc.2015.10.008
Autor:
J. Wang, Christopher G. Wood, Chad Tang, Andrew J. Bishop, Q.N. Nguyen, Amado Zurita-Saavedra, Amishi Yogesh Shah, Matthew T. Campbell, J. Li, Surena F. Matin, Jose A. Karam, Nizar M. Tannir, Amol J. Ghia, Pavlos Msaouel, Eric Jonasch, Debra Nana Yeboa, Aradhana M. Venkatesan, Brian De
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:e871
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b6dddebe598c27a4c66d7362041f9a8
https://doi.org/10.1016/j.ijrobp.2020.07.450
https://doi.org/10.1016/j.ijrobp.2020.07.450